secwatch.observer — SEC 8-K summary
======================================

Issuer:     Akebia Therapeutics, Inc. (AKBA)
CIK:        0001517022
Form:       8-K
Filed at:   2023-11-21T23:59:59+00:00
Accession:  0001517022-23-000044
Event type: litigation
Sentiment:  neutral
Materiality: 0.50
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Akebia settles all patent disputes with FibroGen and Astellas in EU, UK, Japan
------------------------------------------------------------------------------

- Settlement covers European (UK) Patent Nos. 2289531, 1463823, 2322155, 1633333, 2322153, 2298301 and Japanese Patent Nos. 4845728, 5474741, 5474872.
- Resolves FibroGen's opposition to Akebia's European Patent No. 3357911 before the European Patent Office.
- All ongoing litigation in UK courts and Japan Intellectual Property High Court to be terminated under agreement.
- No financial terms or other business impact disclosed in the filing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1517022/000151702223000044/0001517022-23-000044-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1517022/000151702223000044/akba-20231121.htm
  HTML page:      https://secwatch.observer/filing/0001517022-23-000044

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer